Reslizumab

Drug Overview

Time taken to compute- 0.015 sec

drug details
nameReslizumab
classificationBiologic; anti-interleukin-5 monoclonal antibody
pharmacokineticsReslizumab is administered intravenously. Peak serum concentrations are typically observed within a few hours. The elimination half-life is approximately 20-30 days, resulting in prolonged therapeutic effects after a single dose. Significant hepatic metabolism isn't a major factor; however, renal function can influence the clearance rate.
suggested dosageThe recommended dosage for Reslizumab in severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwnp) is based on a weight-based titration regimen and is individualized by healthcare providers. Specific dosage information, including weight-adjusted regimens, should be obtained from the prescribing information. It's crucial to discuss appropriate dosages with a healthcare professional, as they will take into account individual patient characteristics.
indicationsReslizumab is indicated for the treatment of severe eosinophilic asthma in adults and adolescents (12 years and older) who have persistent symptoms despite high-dosage inhaled corticosteroids (ICS) and other controller medicines. It is also indicated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwnp).
safety in pregnancyLimited data exists regarding the safety of reslizumab in pregnancy. The potential risks and benefits should be thoroughly discussed with the prescribing physician, considering the severity of the condition and available alternatives. No clear guidelines for use during pregnancy are available, and pregnant patients need careful evaluation.
safety in breastfeedingThere is insufficient data to determine the safety of reslizumab in breastfeeding mothers. Reslizumab may pass into breast milk; therefore, potential risks and benefits for both the mother and the infant must be evaluated and discussed with a healthcare professional. Breastfeeding should be evaluated as a potential risk-benefit choice.
side effects
1Injection site reactions (pain, redness, swelling)
2Nasopharyngitis
3Upper respiratory tract infection
4Headache
5Injection site reactions
6Injection-site pain, redness, and swelling
7Influenza
8Nausea
9Diarrhea
10Myalgia
11Arthralgia
12Fatigue
13Cough
14Abdominal pain
15Pharyngolaryngeal pain
16Increased risk of infections (e.g., cellulitis, sinusitis, upper respiratory tract infections)
17Rarely: serious allergic reactions (anaphylaxis), hypersensitivity reactions, and severe skin reactions
18Very rare: liver problems, kidney problems, and neurological issues
alternatives
1Mepolizumab
2Dupilumab
3Omalizumab
contraindicationsReslizumab is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Existing active infections of severe nature could potentially pose a risk, and the assessment of those risks and benefits needs to be individualized by the physician.
interactionsNo significant drug interactions are known at present. But, drug-drug interactions are not completely understood, and healthcare providers should carefully consider any concurrent medications when prescribing Reslizumab.
warnings and precautions
1Monitor for allergic reactions during and after infusions.
2Close monitoring of renal and hepatic functions is crucial.
3Patients with a history of severe infections, should be carefully evaluated.
4Infusion-related reactions can occur.
5Regular monitoring for infections is important.
additional informationsReslizumab is an expensive treatment and may not be suitable for all patients. A thorough assessment of the patient's condition and needs is required before prescribing.
patient profile
age25
weight70
gendermale

Check another drug or interactions

Most Frequent Searches

Reference Patient:(25 years,Male, 70KGs) *Not a medical advice

Get in Touch Now!

Contact Us